Uso intermitente de etanercept en psoriasis

Herrera, Enrique; Alcaide, A.J.

doi:10.1016/s0001-7310(10)70004-1

Cited by 2 publications

(4 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A further 22 relevant associated articles were found. Excluding duplications, a total of 52 relevant articles were identified …”

Section: Resultsmentioning

confidence: 99%

“…Excluding duplications, a total of 52 relevant articles were identified. [1][2][3][4]6,7,9, Table 1 summarises the agreed key findings of the literature search, grouped under themes of adherence, 11,12 decision-making, [13][14][15][16][17] quality of life, [18][19][20][21][22] patient/physician goals, [23][24][25] questionnaire, 26 patient-reported outcomes, 3 satisfaction, 6,27 and PBI. 9,28 A number of search terms returned no relevant articles (for example, attitude, belief, infection, life events, patient expectations, perception, pregnancy, vaccination), suggesting gaps in the data in these areas.…”

Section: Resultsmentioning

confidence: 99%

“…No biological can be considered best for all patients 11 Patient preference should be a major deciding factor in biological choice 11 The dermatologist is the most important source for patient understanding of biologics, followed by research on the internet 12 The life course of patients has an impact on treatment strategies 13,14 Fear of adverse effects is an important factor in patient preference 11,15 Quality of life Treatment strategy has an impact on DLQI 16 Patients on topical and traditional systemic therapies have higher DLQI scores 16,17 Patients with high DLQI and PASI scores benefit most from biologics 18 Skindex-29, a QoL scoring system, does not correlate with improvements in PASI 19 DLQI is an independent predictor of work productivity 20…”

Section: Decision Makingmentioning

confidence: 99%

See 2 more Smart Citations

A patient‐centred approach to biological treatment decision making for psoriasis: an expert consensus

Strohal

Prinz

Girolomoni

et al. 2015

Acad Dermatol Venereol

View full text Add to dashboard Cite

BackgroundEach individual psoriasis patient has different expectations and goals for biological treatment, which may differ from those of the clinician. As such, a patient‐centred approach to treatment goals remains an unmet need in psoriasis.ObjectiveThe aim of this study was to review available data on patients’ and physicians’ decision criteria and expectations of biological treatment for moderate‐to‐severe psoriasis with the aim of developing a core set of questions for clinicians to ask patients routinely to understand what is important to them and thus better align physicians’ and patients’ expectations of treatment with biologics and its outcomes.MethodsA literature search was conducted to identify key themes and data gaps. Aspects of treatment relevant when choosing a biological agent for an individual patient were identified and compared to an existing validated instrument. A series of questions aimed at helping the physician to identify the particular aspects of treatment that are recognised as important to individual psoriasis patients was developed.ResultsKey findings of the literature search were grouped under themes of adherence, decision‐making, quality of life, patient/physician goals, communication, patient‐reported outcomes, satisfaction and patient benefit index. Several aspects of treatment were identified as being relevant when choosing a biological agent for an individual patient.The questionnaire is devised in two parts. The first part asks questions about patients’ experience of psoriasis and satisfaction with previous treatments. The second part aims to identify the treatment attributes patients consider to be important and may as such affect their preference for a particular biological treatment. The questionnaire results will allow the physician to understand the key factors that can be influenced by biological drug choice that are of importance to the patient. This information can be used be the physician in clinical decision making.ConclusionThe questionnaire has been developed to provide a new tool to better understand and align patients’ and physicians’ preferences and goals for biological treatment of psoriasis.

show abstract

“…A further 22 relevant associated articles were found. Excluding duplications, a total of 52 relevant articles were identified …”

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Decision Makingmentioning

confidence: 99%

See 1 more Smart Citation

A patient‐centred approach to biological treatment decision making for psoriasis: an expert consensus

Strohal

Prinz

Girolomoni

et al. 2015

Acad Dermatol Venereol

View full text Add to dashboard Cite

show abstract

“…The CRYSTEL trial and a review of pivotal and postmarketing randomized controlled trials of etanercept treatment have also reported that the efficacy of etanercept is retained in the long-term ( 54 weeks), regardless of whether therapy was interrupted or continuous (18,19). According to clinical experience of efficacy profiles gained by Italian dermatological centers, real-world practice confirms that flexible dosing with etanercept is a valuable therapeutic tool for the management of patients with psoriasis considered to be high-need (20).…”

Section: Discussionmentioning

confidence: 91%